Drugs / Recombinant GH
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00553852 | Jul 2007 → Jan 2008 | obesity disorder | Federico II University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant GH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00553852 ↗ |
| Known as | Saizen | “Recombinant GH Saizen (Merck-Serono)” NCT00553852 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human GH” PMID 19066295 ↗ Dec 2008 |